AXIL reduces authorized common from 450M to 15M shares; preferred from 300M to 28M shares

Axil Brands, Inc.

On May 19, 2025, AXIL filed a Certificate of Amendment decreasing authorized common from 450M to 15M shares.
Authorized preferred stock reduced from 300M to 28M shares; Series A Preferred decreased from 250M to 27,773,500 shares.
Amendment approved by majority stockholder written consent as disclosed in the April 28, 2025 Schedule 14C.
Change effective upon filing with Delaware Secretary of State on May 19, 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Axil Brands, Inc.: Decreased authorized shares of common stock from 450,000,000 to 15,000,000, preferred stock from 300,000,000 to 28,000,000, and Series A Preferred from 250,000,000 to 27,773,500 (effective 2025-05-19).

Change: charter amendment
Effective: 2025-05-19

Exact text from the filing

On May 19, 2025, AXIL Brands, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (“Certificate of Amendment”) with the Delaware Secretary of State to decrease the number of authorized shares of the Company’s common stock, par value $0.0001 per share, from 450,000,000 shares to 15,000,000 shares and to decrease the number of authorized shares of the Company’s preferred stock, par value $0.0001 per share, from 300,000,000 shares to 28,000,000 shares and correspondingly decrease the number of shares of preferred stock designated as Series A Preferred Stock from 250,000,000 shares to 27,773,500 shares, which was effective upon filing.

View on SEC.gov

Browse all governance changes →

Axil Brands, Inc. filing history →

Source: SEC EDGAR

accession 0001520138-25-000158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.